IMUNON enters into technology evaluation agreement with

IMUNON enters into technology evaluation agreement with

Successful combination of technologies. Will expand the opportunities for meSTUMP‘s based on DNA modality and expand requests for the PLACINE northucleic aacid vacina pplatform What anorth alternative to mRNA and protein vaccines

LAWRENCEVILLE, NJ and VANCOUVER, BC, Nov. 10, 2022 (GLOBE NEWSWIRE) — meSTUMPInc. (NASDAQ: IMNN), a clinical-stage drug development company, and Acuitas Therapy, a private biotechnology company focused on the development of nucleic acid vaccine delivery systems and lipid nanoparticle (LNP)-based therapeutics, today announced the signing of an agreement to evaluate IMUNON’s PLACCINE nucleic acid vaccine construct combination Formulated with Acuitas’ patented lipid delivery technology. Under the agreement, IMUNON will evaluate delivery of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

“We are delighted to enter into this technology assessment agreement with Acuitas Therapeutics, an organization recognized for its technological delivery capabilities, particularly with its LNP systems for mRNA vaccines,” said Corinne Le Goff, Ph.D., President and CEO. of IMUNÓN. “In light of recent successes with our PLACCINE technology and promising proof-of-concept data from SARS CoV-2 in non-human primates, we believe the time is right to explore expanding our technology to other types of delivery systems. as we go. position our nucleic acid-based modality as the future of vaccinology.”

IMUNON has demonstrated initial proof-of-concept of its PLACCINE nucleic acid vaccine platform in rodent and non-human primate models by intramuscular (IM) administration of PLACCINE plasmid DNA constructs expressing one or more SARS-CoV-2 antigen(s). in combination with PLACCINE delivery system. In October 2022, IMUNON reported partial results of an ongoing study in non-human primates that examined a single plasmid DNA vector containing the SARS-CoV-2 alpha variant spike antigen formulated with a delivery system. synthetic DNA. In the study, Cynomolgus monkeys were vaccinated with the PLACCINE vaccine or a commercial mRNA vaccine on days 1, 28, and 84.

Analysis of blood samples for IgG and neutralizing antibodies showed evidence of immunogenicity in subjects vaccinated with PLACCINE and mRNA. Bronchoalveolar lavage PCR analysis showed viral shedding in >90% of unvaccinated controls. In most vaccinated animals, viral shedding from the nasal swab followed a similar pattern and a similar shedding profile was observed when viral load was analyzed by the tissue culture infective dose method. In an ongoing stability study, the physicochemical properties and immunogenicity of PLACCINE vaccine did not change during storage at 4°C for up to six months.

Thomas Madden, Ph.D., president and CEO and co-founder of Acuitas Therapeutics, said, “We are excited to collaborate with IMUNON to evaluate nucleic acid-based vectors delivered using our LNP technology.”

Acuitas Therapeutics was founded by Drs. Pieter Cullis, Michael Hope and Thomas Madden, who in September 2022 received Canada’s Governor General’s Innovation Award. This prestigious award recognized his work in developing LNP systems to deliver anticancer drugs to tumors and enable the therapeutic use of RNA- and DNA-based drugs. Among other achievements, his work resulted in the LNP system that allows COMRINATY®the Pfizer/BioNTech COVID-19 mRNA vaccine.

About the PLACCINE Platform

PLACCINE, part of IMUNON’s proprietary nucleic acid technology with synthetic delivery systems platform, is the subject of multiple patent applications covering a wide range of next-generation nucleic acid vaccines. An adaptation of the company’s TheraPlas technology for therapeutic proteins, PLACCINE is a prophylactic vaccine modality characterized by a single nucleic acid vector with multiple coding regions. The vaccine vector is designed to express multiple pathogenic antigens along with the option to include a potent immune modifier. PLACCINE has the potential to be easily modified to create vaccines against a multitude of infectious diseases, with benefits including:

  • Durability of protection: long-lasting antigen expression induces a robust immune response
  • Breadth of protection: multicistronic vectors increase the breadth of the immune response and allow combination vaccines
  • Transmission advantage: the option for co-expression of potent immune modifiers increases the immune response and reduces the risk of viral shedding
  • Safe and convenient: Synthetic delivery systems do not present a risk of genotoxicity (ie, they do not have viruses or cytotoxicity) and do not require any device; also allows convenient handling for pandemic control
  • Flexible Manufacturing: Versatile platform enables rapid response to changing pathogens; stability at normal refrigerator temperatures simplifies handling and distribution

On immunon

IMUNON is a fully integrated clinical-stage biotechnology company focused on promoting a portfolio of innovative therapies that harness the body’s natural mechanisms to deliver safe, effective, and long-lasting responses across a wide range of human diseases, a differentiating approach from conventional therapies.

IMUNON has two platform technologies: TheraPlas® platform for the development of immunotherapies and other anticancer therapies based on nucleic acids, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that is currently in phase II development. GEN-1 works by instructing the body to produce safe and long-lasting levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. In addition, the company is conducting proof-of-concept preclinical studies on a nucleic acid vaccine candidate targeting the SARS-CoV-2 virus to validate its PLACCINE platform. IMUNON’s platform technologies are based on nucleic acid delivery with novel synthetic delivery systems that are independent of viral vectors or devices. IMUNON will continue to leverage these platforms and advance the technological frontier of nucleic acid-based products to better serve patients with difficult-to-treat conditions. For more information about IMUNON, visit imunon.com.

On Acuitas Therapy

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapies based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapy in clinical trials and to market. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of vaccines against COVID-19. These include Pfizer/BioNTech for COMIRNATY®, which has received full approval in the US and Canada and is authorized for emergency use in Europe, the UK and many other countries. The Acuitas team is currently working on therapies focused on the treatment of cancer, HIV/AIDS, tuberculosis, malaria, rabies and other serious diseases.

Forward-looking statements

meSTUMP wishes to inform readers that the forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, unforeseen changes in the course of research and development activities and in clinical trials; uncertainties and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for meSTUMP evaluate your future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in ISTUMPPeriodic reports and prospectuses filed with the Securities and Exchange Commission. meSTUMP undertakes no obligation to update or supplement any forward-looking statements that become false due to subsequent events, new information or otherwise.

Contacts:
immunon
Church of Jeffrey W.
Executive Vice President, CFO and Corporate Secretary
609-482-2455
jchurch@imunon.com

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

Acuitas therapeutic means
604-846-8461
media@acuitastx.com

# # #

Leave a Comment